MOHAMMAD IMTIAZ MUBBASHAR: Open Payments
NPI 1619497823 · PETERSBURG, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$348 in 15 payments from 9 companies in 2025. Trend: 2023 $320 · 2024 $835 · 2025 $348
Food & beverage: $348
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 4 | $118 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $33 |
| Alkermes, Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Neurocrine BioSciences, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
Products named: COBENFY, FANAPT, TRINTELLIX, CAPLYTA, ARISTADA, UZEDY, Qelbree, INGREZZA.
Industry payments across VA — which companies pay providers there.
